Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11452803 | 0.97 | TSHR (0.40) | TSHRHSD17B10FBP1CES2CES1 | |
| SCHEMBL1306575 | 0.82 | KDM1A (0.36) | TSHRHSD17B10FBP1CES2CES1 | |
| Hydrochloric Acid SCHEMBL11776201 | 0.80 | KDM1A (0.35) | TSHRHSD17B10FBP1SMN1; SMN2DAO | |
| Tiodonium SCHEMBL2110688 | 0.78 | LMNA (0.37) | TSHRHSD17B10NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL192766 | 0.77 | RAB9A (0.36) | TSHRFBP1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11777898 | 0.77 | L3MBTL1 (0.38) | TSHRHSD17B10FBP1NPC1RAB9A | |
| Tiodonium SCHEMBL192767 | 0.77 | LMNA (0.36) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| Tiodonium SCHEMBL1305415 | 0.77 | LMNA (0.36) | NPC1RAB9ASMN1; SMN2MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1305368 | 0.76 | MAPT (0.34) | MEN1ALDH1A1KMT2AMAPTKDM4E | |
| Bromide SCHEMBL1306253 | 0.76 | MAPT (0.34) | MEN1ALDH1A1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263323-A1 | Novel means and methods for the treatment of hearing loss and phantom hearing | UNIVERSITY OF GENEVA | 2009-10-22 | — | — | US | claimed |
| WO-2009044294-A2 | MEANS AND METHODS FOR THE TREATMENT OF CATARACT AND PRESBYOPIA | UNIVERSITÉ DE GENEVE (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1923702-A2 | Novel means and methods for the treatment of hearing loss and phantom hearing | University of Geneva (CH) | 2008-05-21 | — | — | EP | claimed |
| EP-1766390-A2 | NOVEL MEANS AND METHODS FOR THE TREATMENT OF HEARING LOSS AND PHANTOM HEARING | University of Geneva (CH) | 2007-03-28 | — | — | EP | claimed |
| WO-2005119251-A2 | NOVEL MEANS AND METHODS FOR THE TREATMENT OF HEARING LOSS AND PHANTOM HEARING | UNIVERSITY OF GENEVA (CH) | 2005-12-15 | — | — | WO | claimed |
| US-20020081277-A1 | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, NIH | 2002-06-27 | — | — | US | claimed |
| US-6375944-B1 | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2002-04-23 | — | — | US | claimed |
| EP-3129102-B1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | US HEALTH (US) | 2025-06-18 | — | — | EP | disclosed |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | THE US SECRETARY DEPARTMENT OF HEALTH (US) | 2019-02-14 | — | — | US | disclosed |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| US-9829605-B2 | Polarized film, optical film, and image display device | NITTO DENKO CORPORATION (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9650635-B2 | Pharmaceutical compositions comprising small interfering RNA inhibitors of NOX3 | UNIVERSITY OF GENEVA (CH) | 2017-05-16 | — | — | US | disclosed |
| EP-0870763-A1 | Condensed piperidine derivatives used as a nitrogen monoxide synthase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998033379-A1 | A NOVEL METHOD FOR TREATING EPIDERMAL OR DERMAL CONDITIONS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0754023-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 1997-01-22 | — | — | EP | disclosed |
| EP-0729356-A1 | USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES | DUKE UNIVERSITY MEDICAL CENTER (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5468476-A | Enzyme inhibitor | GILLETTE CO., THE | 1995-11-21 | — | — | US | disclosed |
| WO-1995024884-A1 | INHIBITION OF HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1995-09-21 | — | — | WO | disclosed |
| WO-1995013805-A1 | USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES | DUKE UNIVERSITY MEDICAL CENTER (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263323-A1 | Novel means and methods for the treatment of hearing loss and phantom hearing | DAB2IP, STUB1, ATP5PD | TSHR 4394/4885HSD17B10 3129/4885FBP1 1744/4885 |
| US-20190048001-A1 | IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF | NOX5, CYBB, NOX1 | TSHR 3202/4885HSD17B10 146/4885FBP1 565/4885 |
| US-10131659-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | TSHR 3202/4885HSD17B10 146/4885FBP1 565/4885 |
| US-10738047-B2 | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | NOX5, CYBB, NOX1 | TSHR 3202/4885HSD17B10 146/4885FBP1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.